An assessment of quality of life using electronic patient-reported outcome (ePRO) in patients receiving second-line chemotherapy for unresectable pancreatic cancer
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000044245
- Lead Sponsor
- Public Health Research Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Judged ineligible to enroll by principal or sub-investigator (2) Currently receiving 2nd cycle of second-line chemotherapy for unresectable advanced or metastatic pancreatic cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EQ-5D-5L index values measured during 2 consecutive cycles of the second-line chemotherapy after enrolment, beginning at the first day of the 2nd cycle of the chemotherapy.
- Secondary Outcome Measures
Name Time Method (1) QALD calculated from the EQ-5D-5L index value and EORTC QLQ C-30 global score in the study period. (2) EORTC QLQ-C30 global and domain scores during the study period. (3) Correlation between QOL scores and frequency and severity of adverse events as defined in PRO-CTCAE.